|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01181505 |
|
Date of registration:
|
12/08/2010 |
|
Primary sponsor: |
|
|
Public title:
|
STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study
HNF4a |
|
Scientific title:
|
STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study |
|
Date of first enrolment:
|
January 2007 |
|
Target sample size:
|
31 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT01181505 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
|
|
|
Contacts
|
|
Name:
|
Jae-Gook Shin, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Inje University |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Healthy subject whose HNF4a and CYP2D6 genotype ware determined
Exclusion Criteria:
- Subject whose HNF4a and CYP2D6 genotype ware not determined
Age minimum:
20 Years
Age maximum:
65 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Genotype Guided(HNF4a)
|
|
Healthy Subjects
|
|
Intervention(s)
|
|
Drug: Tolterodine
|
|
Primary Outcome(s)
|
|
Cmax, AUC, CL, Vd, T1/2
[Time Frame: 24hr]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|